Resprecare

Resprecare is a clinical-stage biopharmaceutical company specializing in the development of high-end inhaled medications for respiratory diseases. Based in Suzhou, China, the company utilizes its proprietary dry powder inhaler (DPI) and metered-dose inhaler (MDI) technology platforms to develop a robust pipeline of treatments for COPD and asthma. Its lead candidates include combinations of long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS). Resprecare aims to provide high-quality, cost-effective alternatives to global blockbuster respiratory drugs while expanding into innovative therapeutic areas. The company is recognized for its integrated approach, combining device engineering with pharmaceutical formulation to overcome the technical barriers of inhaled drug delivery.